Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 8/20 | 0.46 |
| ▸ | GSK3B | P49841 | 4/20 | 0.46 |
| ▸ | FLT1 | P17948 | 4/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.44 |
| ▸ | FLT4 | P35916 | 2/20 | 0.44 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | RAF1 | P04049 | 2/20 | 0.42 |
| ▸ | BRAF | P15056 | 2/20 | 0.42 |
| ▸ | IGF1R | P08069 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.42 |
| ▸ | TEK | Q02763 | 1/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 5/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5357333 | 0.85 | RAF1 (0.48) | KDRGSK3BFLT1FGFR1FLT4 | |
| SCHEMBL5359718 | 0.82 | EGFR (0.62) | KDRGSK3BSRCEGFR | |
| SCHEMBL14355895 | 0.78 | GSK3B (0.47) | KDRGSK3BEGFR | |
| SCHEMBL5354432 | 0.76 | MEN1 (0.45) | KDRGSK3BMEN1KMT2AMAPT | |
| SCHEMBL5361906 | 0.75 | EGFR (0.49) | KDRGSK3BRAF1BRAFEGFR | |
| SCHEMBL5362131 | 0.72 | ALK (0.45) | KDRGSK3BMEN1KMT2AMAPT | |
| SCHEMBL5097637 | 0.72 | KDR (0.60) | KDRFLT1FGFR1FLT4EPHB2 | |
| SCHEMBL5356238 | 0.71 | GABRP (0.48) | KDRGSK3BMEN1KMT2AMAPT | |
| SCHEMBL5358390 | 0.70 | ABCG2 (0.53) | KDRGSK3BMEN1KMT2AMAPT | |
| Hydrochloric Acid SCHEMBL1470089 | 0.70 | KDR (0.58) | KDRFLT1FGFR1FLT4EPHB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7294633-B2 | Oxazolo-and furopyrimidines and their use in medicaments against tumors | NOVARTIS AG (CH) | 2007-11-13 | — | — | US | claimed |
| EP-1390371-B1 | OXAZOLO-AND FUROPYRIMIDINES AND THEIR USE IN MEDICAMENTS AGAINST TUMORS | NOVARTIS AG (CH) | 2006-03-08 | — | — | EP | claimed |
| US-20040152892-A1 | Oxazolo-and furopyrimidines and their use in medicaments against tumors | NOVARTIS AG (CH) | 2004-08-05 | — | — | US | claimed |
| US-7294633-B2 | Oxazolo-and furopyrimidines and their use in medicaments against tumors | NOVARTIS AG (CH) | 2007-11-13 | — | — | US | disclosed |
| EP-1390371-B1 | OXAZOLO-AND FUROPYRIMIDINES AND THEIR USE IN MEDICAMENTS AGAINST TUMORS | NOVARTIS AG (CH) | 2006-03-08 | — | — | EP | disclosed |
| US-20040152892-A1 | Oxazolo-and furopyrimidines and their use in medicaments against tumors | NOVARTIS AG (CH) | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152892-A1 | Oxazolo-and furopyrimidines and their use in medicaments against tumors | DPYD, COXFA4L2, MSH2 | KDR 2394/4885GSK3B 1026/4885FLT1 826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.